Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab Combinations in Myeloid Malignancies
NCT04778410Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of magrolimab in acute myeloid leukemia (AML), sponsored by Gilead Sciences. Started Jun 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04778410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778410.